246 related articles for article (PubMed ID: 36419390)
1. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
[TBL] [Abstract][Full Text] [Related]
2. Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Fu Y; Zhang Y; Lei Z; Liu T; Cai T; Wang A; Du W; Zeng Y; Zhu J; Liu Z; Huang JA
J Hematol Oncol; 2020 Dec; 13(1):169. PubMed ID: 33287873
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
4. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
5. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.
Shuai S; Liao X; Wang H; Liu L; Mei S; Cao J; Wang S
Cancer Sci; 2021 Oct; 112(10):4139-4150. PubMed ID: 34058054
[TBL] [Abstract][Full Text] [Related]
6. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
7. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
9. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
10. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
11. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma.
Zhou S; Deng M; Bian X; Shi J; Liang R; Tao M
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):120-127. PubMed ID: 38430032
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
14. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
[TBL] [Abstract][Full Text] [Related]
15. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
16. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
17. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
18. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
19. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Wu DW; Chen TC; Huang HS; Lee H
Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
[TBL] [Abstract][Full Text] [Related]
20. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
Xie M; He J; He C; Wei S
J Cell Biochem; 2015 Jun; 116(6):1019-27. PubMed ID: 25561332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
